Here are key growth drivers behind Holista Colltech’s (ASX:HCT) infection control division

Highlights

• Holista Colltech is a recognised research-driven biotech company providing natural wellness solutions to people worldwide.
• The company’s newest division offers infection control solutions like all-natural Super Bio Nano Silver, which kills 99.99% of human coronavirus strain.
• In Q1, the division posted a 164% jump in sales.

Headquartered in Perth, Holista Colltech Limited (ASX:HCT) is a research-driven biotech company providing natural wellness solutions. The ASX-listed company is involved in the research & development of natural daily lifestyle products that can fulfil the growing needs of its customers.

In this article, we will catch a glimpse of one of its business divisions dedicated to the innovation, manufacturing, and marketing of infection control solutions.

The division commenced its operations in 2020 with the prime goal of providing people with all-natural, non-toxic, and effective sanitising products. The division offers a range of natural and alcohol-free sanitising solutions that have been effective against viruses, including COVID-19.

The ASX-listed firm hosts a rich portfolio of patent-protected and proprietary technologies and runs a wide network of operations across Malaysia.

What’s more, the division registered a 164% increase in sales for the quarter ended 31 March 2022.

Do read: What’s behind Holista Colltech’s (ASX:HCT) bullish FY22 outlook in this volatile market?

Flagship products under Infection Control Division

Source: Company website

• Holista has a global collaboration with Global Infection Control Consultants LLC to use Path-Away®, a plant-based solution that is proven to kill a broad spectrum of microbes, including SARS-CoV-2 (the virus that causes COVID-19). The all-natural alcohol-free active ingredient is used in Holista’s range of products under the Natshield™ brand.

• Holista’s SARS-CoV-2 rapid test kit branded as “Gene Sign” is in the process of securing final approval from the regulators in Colombia. Once Gene Sign receives this approval, it will get corresponding approvals in Brazil, Argentina and Mexico as the four countries share a mutual agreement. Also, Gene Sign has set in motion the process of securing approval in North America as per the Medical Device Single Audit Program (MDSAP) with the United States Food and Drug Administration (FDA).

In the United Kingdom, final evaluation is underway for Gene Sign’s Reverse Transcription Loop-Mediated Isothermal Amplification (RT-LAMP) technology to obtain COVID Testing Devices Authorisation (CTDA). Upon approval, it will be allowed to be sold in the UK market.

• In the March 2022 quarter, Holista’s all-natural Super Bio Nano Silver disinfectant developed on its proprietary technology was independently tested by SGS (Malaysia) and found to kill 99.99% of the human coronavirus (ATCC VR-740) strain within 30 minutes. At present, the product is being sold by a Malaysian distributor called Bamboo Earth Sdn Bhd in Malaysia and is in discussion for region market distribution.

ALSO READ: Holista’s all-natural disinfectant kills 99.99% of human coronavirus strain, confirms test

How is this division drafting HCT’s success story?

The infection control solution business holds strong multi-year growth potential. Its maiden contribution to the Group in FY2020 was AU$0.67 million, accounting for about 10% of the total revenue of the firm. It was well above the target set for the division for the first year of its operations.

The sales of the Infection Control Division doubled in 1Q 2022 on pcp to AU$18,000, after the successful launch of its all-natural Super Bio Nano Silver disinfectant. The Company also recently launched a nasal protecting balm, which is also expected to contribute to the growth of this business.

There are a series of new and upcoming products to be launched soon. The company ensures that all of its products are tested and approved by the World Health Organization (WHO), United States Environmental Protection Agency (EPA), FDA, and other relevant health authorities.  

Stock information: HCT shares last traded at AU$0.030 on the ASX. The company has a market capitalisation of AU$8.26 million.